Medicamen Biotech Ltd (MEDICAMEQ) — Board Meeting | 3 September 2026

Medicamen Biotech Ltd announced its 33rd AGM on September 26, 2026, via video conferencing, with e-voting from September 23-25. The meeting will adopt FY2025-26 financials showing 18.1% revenue growth to ₹178.84 Crores and 49.43% PAT increase to ₹979.64 Lakhs. Key resolutions include preferential allotment of 8,48,215 equity shares and 6,50,000 convertible warrants at ₹530 each, appointment of new directors including Whole-time Executive Director Ashwani Kumar Sharma, and reconstitution of governance committees. The filing highlights governance concerns including a ₹7,080 NSE fine for delayed shareholding filing and a ₹1,10,920 penalty for improper Nomination and Remuneration Committee composition. Shareholding stands at 99.69% dematerialised, with ₹25.20 Lakhs CSR spend against a ₹31.33 Lakhs statutory requirement.